IP Library Granted Patent US 12,290,597
Granted Patent B2
US 12,290,597 · App. 18/091,556 · Granted May 6, 2025

Oral film compositions and dosage forms having precise active dissolution profiles

Inventors: Alexander Mark Schobel (Vero Beach, FL); Stephen Wargacki (Pittstown, NJ); Vincent J. Buono (Basking Ridge, NJ); Susan Shumard (Green Brook, NJ); Christopher James Santee (Portage, IN)
Assignee: Aquestive Therapeutics, Inc.
A61K9/006A61K31/5513A61P25/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,290,597
App. No.
18/091,556
Granted
May 6, 2025
Kind
B2
Abstract

An oral film in an individual unit dose for delivery of one or more actives is disclosed herein, the film having a precisely calculated and controlled active dissolution profile. A wide variety of actives may be used, including, for example, clobazam, diazepam, or riluzole. Also disclosed are methods of treating a variety of diseases and conditions, for example, epilepsy and seizures, by administering the oral film disclosed herein.

Claims (18)

1. A self-supporting oral film for delivery of a desired amount of an active in an individual unit dose, said film comprising:

a) a water-soluble polymer matrix, a water swellable polymer matrix, or a water-soluble and water swellable polymer matrix;

b) the active being clobazam and having an average particle size D90 of less than about 160 microns; and

c) an additive selected from the group consisting of a sweetener, a flavor, a flavor enhancer, a filler, a plasticizer, a dye, a pigment, a permeation enhancer, a buffer, a preservative, silicon dioxide, an anti-tacking agent, and any combination thereof;

wherein, upon placing the film in a medium, about 30% or more of the active is dissolved in the medium after about 3 minutes.

2. The film of claim 1 , wherein the active has an average particle size D90 of less than about 120 microns.

3. The film of claim 1 , wherein the active has an average particle size D50 of less than about 30 microns.

4. The film of claim 2 , wherein the active has an average particle size D10 of less than about 10 microns.

5. The film of claim 1 , wherein the individual unit dose contains about 2 mg to about 20 mg of clobazam.

6. The film of claim 5 , wherein the individual unit dose contains about 5 mg of clobazam.

7. The film of claim 5 , wherein the individual unit dose contains about 10 mg of clobazam.

8. The film of claim 5 , wherein the individual unit dose contains about 20 mg of clobazam.

9. A method of treating epilepsy and/or seizures in a human comprising administering to said human the oral film individual unit dose of claim 1 .

10. The film of claim 1 , wherein the water-soluble polymer matrix, the water swellable polymer matrix, or the water-soluble and water swellable polymer matrix comprise a polymer selected from polyethylene oxide (PEO), pullulan, hydroxypropylmethyl cellulose (HPMC), hydroxyethyl cellulose, hydroxypropyl cellulose (HPC), polyvinyl pyrrolidone, carboxymethyl cellulose, polyethylene glycol, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methyl-methacrylate copolymer, carboxyvinyl copolymers, starch, gelatin, and combinations thereof.

11. The film of claim 10 , wherein the polymer is polyethylene oxide (PEO).

12. The film of claim 11 , wherein the polyethylene oxide has a molecular weight of at least about 100,000.

13. The film of claim 11 , wherein the polyethylene oxide has a molecular weight from about 100,000 to 300,000.

14. The film of claim 1 , wherein the active has an average particle size D90 of about 8 microns to no more than about 160 microns.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded May 13, 2026
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 075646/0258 →
SECURITY INTEREST Recorded May 12, 2026
From: AQUESTIVE THERAPEUTICS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 075561/0782 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2025
From: SCHOBEL, ALEXANDER MARK; WARGACKI, STEPHEN; BUONO, VINCENT J.; SHUMARD, SUSAN; SANTEE, CHRISTOPHER JAMES
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 070652/0231 →
SECURITY INTEREST Recorded Nov 2, 2023
From: AQUESTIVE THERAPEUTICS, INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 065446/0494 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2023
From: SCHOBEL, ALEXANDER MARK; WARGACKI, STEPHEN; BUONO, VINCENT J.; SHUMARD, SUSAN; SANTEE, CHRISTOPHER JAMES
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 063864/0220 →
Continuity (4)
Continuation 16561573 · Sep 5, 2019
Provisional Application 62732720 · Sep 18, 2018
Provisional Application 62728187 · Sep 7, 2018
Related Publication 20230145752A1 · May 11, 2023
References Cited (94)
US 4631837A · Magoon · 1986 [cited by applicant]
US 6552017B1 · Robichaud et al. · 2003 [cited by applicant]
US 6713471B1 · Robichaud et al. · 2004 [cited by applicant]
US 7071186B2 · Robichaud et al. · 2006 [cited by applicant]
US 7183282B2 · Robichaud et al. · 2007 [cited by applicant]
US RE39680E · Robichaud et al. · 2007 [cited by applicant]
US 7357891B2 · Yang et al. · 2008 [cited by applicant]
US 7425292B2 · Yang et al. · 2008 [cited by applicant]
US 7666337B2 · Yang et al. · 2010 [cited by applicant]
US 8012505B2 · Houghton et al. · 2011 [cited by applicant]
US 8017150B2 · Yang et al. · 2011 [cited by applicant]
US 8309722B2 · Tomesch et al. · 2012 [cited by applicant]
US 8598119B2 · Mates et al. · 2013 [cited by applicant]
US 8603514B2 · Yang et al. · 2013 [cited by applicant]
US 8648077B2 · Tomesch et al. · 2014 [cited by applicant]
US 8652378B1 · Yang et al. · 2014 [cited by applicant]
US 8663667B2 · Bui et al. · 2014 [cited by applicant]
US 8765167B2 · Myers et al. · 2014 [cited by applicant]
US 8779139B2 · Tomesch et al. · 2014 [cited by applicant]
US 8900497B2 · Yang et al. · 2014 [cited by applicant]
US 8900498B2 · Yang et al. · 2014 [cited by applicant]
US 8936825B2 · Myers et al. · 2015 [cited by applicant]
US 8956685B2 · Bogue et al. · 2015 [cited by applicant]
US 8993572B2 · Mates et al. · 2015 [cited by applicant]
US 9108340B2 · Yang et al. · 2015 [cited by applicant]
US 9168258B2 · Mates et al. · 2015 [cited by applicant]
US 9315504B2 · Tomesch et al. · 2016 [cited by applicant]
US 9371324B2 · Mates et al. · 2016 [cited by applicant]
US 9428506B2 · Mates et al. · 2016 [cited by applicant]
US 9586960B2 · Tomesch et al. · 2017 [cited by applicant]
US 9616061B2 · Mates et al. · 2017 [cited by applicant]
US 9708322B2 · Li et al. · 2017 [cited by applicant]
US 9745300B2 · Mates et al. · 2017 [cited by applicant]
US 9751883B2 · Tomesch et al. · 2017 [cited by applicant]
US 9855221B2 · Myers et al. · 2018 [cited by applicant]
US 9931305B2 · Yang et al. · 2018 [cited by applicant]
US 10744086B2 · Lim et al. · 2020 [cited by applicant]
US 10857097B2 · Lim et al. · 2020 [cited by applicant]
US 20040034015A1 · Robichaud et al. · 2004 [cited by applicant]
US 20040228919A1 · Houghton et al. · 2004 [cited by applicant]
US 20050037055A1 · Yang et al. · 2005 [cited by applicant]
US 20050281772A1 · Bromley et al. · 2005 [cited by applicant]
US 20120219628A1 · Lim et al. · 2012 [cited by applicant]
US 20120263865A1 · Bogue · 2012 [cited by applicant]
US 20130156823A1 · Wu et al. · 2013 [cited by applicant]
US 20140178473A1 · Lim et al. · 2014 [cited by applicant]
US 20150072964A1 · Mates et al. · 2015 [cited by applicant]
US 20150080404A1 · Mates et al. · 2015 [cited by applicant]
US 20160310502A1 · Vanover et al. · 2016 [cited by applicant]
US 20170056374A1 · Lee et al. · 2017 [cited by applicant]
US 20170114037A1 · Davis et al. · 2017 [cited by applicant]
US 20170183350A1 · Mates et al. · 2017 [cited by applicant]
US 20170189398A1 · Mates et al. · 2017 [cited by applicant]
US 20170290776A1 · Schobel et al. · 2017 [cited by applicant]
US 20170348251A1 · Schobel et al. · 2017 [cited by applicant]
US 20170360942A1 · Myers et al. · 2017 [cited by applicant]
US 20180280518A1 · Myers et al. · 2018 [cited by applicant]
US 20200000773A1 · Lee et al. · 2020 [cited by applicant]
US 20200046637A1 · Lim et al. · 2020 [cited by applicant]
US 20230086496A1 · Lim et al. · 2023 [cited by applicant]
CN 1758899A · 2006 [cited by applicant]
CN 102933207A · 2013 [cited by applicant]
CN 105193772A · 2015 [cited by applicant]
JP 2013253039A · 2013 [cited by applicant]
WO 2004075875A1 · 2004 [cited by applicant]
WO 2011053251A1 · 2011 [cited by applicant]
WO 2017192923A1 · 2017 [cited by applicant]
Aprea, E. et al., “Volatile Compounds of Raspberry Fruit: From Analytical Methods to Biological Role and Sensory Impact,” Molecules 2015, vol. 20, 2445-2474. [cited by applicant]
Pion Rainbow Dynamic Dissolution Monitor (https://pion.com.cn/dissolution/compendial-dissolution/rainbow/) (5 pages). [cited by applicant]
International Search Report issued in PCT/US2019/049725, dated Jan. 28, 2020 (5 pages). [cited by applicant]
Written Opinion of the International Searching Authority issued in PCT/US/2019/049725, dated Jan. 28, 2020 (5 pages). [cited by applicant]
Rajni Bala et al., Design Optimization and In Vitro-In Vivo Evaluation of Orally Dissolving Strips of Clobazam, 2014, Journal of Drug Delivery, vol. 2014, Article ID 392783, pp. 1-15 (Year: 2014). [cited by applicant]
Pharmaceutics, Meng Shengnan et al., Shanghai Scientific & Technical Publishers, pp. 81-83, published on Sep. 30, 2011. [cited by applicant]
First Office Action for Chinese Application No. 201980073077.2 dated Apr. 20, 2023 (in Chinese with English translation). [cited by applicant]
Communication pursuant to Article 94(3) EPC for European Patent Application No. 19 797 393.3-1112 dated Mar. 28, 2023. [cited by applicant]
Preliminary Office Action for Brazilian Patent Application No. BR112021004053-6 dated Jun. 5, 2023 (in Portuguese with Informal English Translation). [cited by applicant]
Official Action (Dispatch Date: Jul. 6, 2023) for Japanese Patent Application No. 2021-512652 in Japanese with English Summary of the Official Action. [cited by applicant]
Official Action (Dispatch Date: Jul. 6, 2023) for Japanese Patent Application No. 2021-512652 in Japanese with English machine translation. [cited by applicant]
Foo, Wen Chin et al., A novel unit-dose approach for the pharmaceutical compounding of an orodispersible film, Int J Pharm. Mar. 25, 2018;539(1-2): 165-174. doi: 10.1016/j. ijpharm.2018.01.047.Epub Feb. 27, 2018. [cited by applicant]
International Preliminary Report on Patentability (Chapter I) issued by the International Bureau of WIPO on behalf of the International Searching Authority for International application No. PCT/US2019/049725, Date of is… [cited by applicant]
Communication pursuant to Article 94(3) EPC from the European Patent Office for European Patent Application No. 19 797 399.3-1112 dated Mar. 28, 2023. [cited by applicant]
Second Office Action issued by the China National Intellectual Property Administration for Chinese Application No. 201980073077.2 dated Dec. 7, 2023 (in Chinese with English translation). [cited by applicant]
Decision on Rejection issued by the China National Intellectual Property Administration for Chinese Application No. 201980073077.2 dated May 9, 2024 (in Chinese with English translation). [cited by applicant]
Office Action issued by the Canadian Intellectual Property Office (CIPO) dated Dec. 8, 2023 for Canadian Patent Application No. 3,110,997. [cited by applicant]
Official Action (Dispatch Date: Apr. 25, 2024) issued by the Japan Patent Office for Japanese Patent Application No. 2021-512652 (in Japanese with English machine translation and with a Brief summary of Official Action … [cited by applicant]
Office Action issued in U.S. Appl. No. 16/561,573, mail date Jun. 22, 2021. [cited by applicant]
Office Action issued in U.S. Appl. No. 16/561,573, mail date Apr. 12, 2022. [cited by applicant]
Office Action issued in U.S. Appl. No. 17/989,307, mail date Jun. 3, 2024. [cited by applicant]
Pre-grant Opposition Petition filed Feb. 28, 2024 with the National Institute of Industrial Property—INPI by EMS S.A. for Brazilian Patent Application No. BR 11 2021 004053 6 (in Portuguese with English Translation). [cited by applicant]
Pre-grant Opposition Petition filed Sep. 20, 2024 with the National Institute of Industrial Property—INPI by Biolab Sanus Farmacêutica LTDA. for Brazilian Patent Application No. BR 11 2021 004053 6 (in Portuguese with E… [cited by applicant]
Shen, Bao-De et al., Development and characterization of an orodispersible film containing drug nanoparticles, European Journal of Pharmaceutics and Biopharmaceutics, vol. 85, Issue 3, Part B, Nov. 2013, pp. 1348-1356, … [cited by applicant]
English Summary of Official Action (Dispatch Date: Jul. 6, 2023) for Japanese Patent Application No. 2021-512652. [cited by applicant]
Communication pursuant to Article 94(3) EPC from the European Patent Office for European Patent Application No. 19 797 399.3-1109 dated Dec. 4, 2024. [cited by applicant]
Office Action issued by the Canadian Intellectual Property Office (CIPO) dated Feb. 6, 2025 for Canadian Patent Application No. 3,110,997. [cited by applicant]